Plain-English translation of NCT07342803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing LP-003, a new injectable medication designed to help people with allergic asthma that remains difficult to control even with standard treatments. The study will compare LP-003 at three different dose levels against both a placebo (inactive injection) and an existing asthma medication called . Researchers want to see if this medication is safe and effective, and how it moves through your body.
Many people with allergic asthma don't get enough relief from their current medications, leading to flare-ups that disrupt their lives. This trial is testing whether the new treatment can reduce these flare-ups and help people breathe better.
You likely qualify if…
You likely don't qualify if…
You will receive an injection under your skin every 4 weeks for the duration of the study. You'll be randomly assigned to receive either one of three doses of the new medication, an existing asthma medication, or a placebo. Throughout the trial, you'll track your asthma symptoms in a diary, attend regular visits to check how you're doing, and complete breathing tests. The study will assess whether the medication reduces your asthma flare-ups and improves how well you can breathe.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Longbio Pharma
Enrollment target
~200 participants
Started
January 2025
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jie Yang
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.